- Home
- IPHA vs CRVO Comparison
IPHA vs CRVO Comparison
Compare IPHA & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- CRVO
- Stock Information
- Founded
- IPHA 1999
- CRVO 2001
- Country
- IPHA France
- CRVO United States
- Employees
- IPHA N/A
- CRVO N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- CRVO Health Care
- Exchange
- IPHA Nasdaq
- CRVO Nasdaq
- Market Cap
- IPHA 148.3M
- CRVO 98.3M
- IPO Year
- IPHA 2019
- CRVO N/A
- Fundamental
- Price
- IPHA $1.79
- CRVO $2.13
- Analyst Decision
- IPHA Strong Buy
- CRVO Buy
- Analyst Count
- IPHA 1
- CRVO 8
- Target Price
- IPHA $11.50
- CRVO $38.75
- AVG Volume (30 Days)
- IPHA 779.8K
- CRVO 476.7K
- Earning Date
- IPHA 09-12-2024
- CRVO 11-12-2024
- Dividend Yield
- IPHA N/A
- CRVO N/A
- EPS Growth
- IPHA N/A
- CRVO N/A
- EPS
- IPHA N/A
- CRVO N/A
- Revenue
- IPHA $36,202,722.00
- CRVO $10,066,550.00
- Revenue This Year
- IPHA N/A
- CRVO $34.17
- Revenue Next Year
- IPHA $101.65
- CRVO N/A
- P/E Ratio
- IPHA N/A
- CRVO N/A
- Revenue Growth
- IPHA N/A
- CRVO 116.29
- 52 Week Low
- IPHA $1.29
- CRVO $1.80
- 52 Week High
- IPHA $3.51
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- IPHA 45.92
- CRVO 28.45
- Support Level
- IPHA $1.64
- CRVO $1.99
- Resistance Level
- IPHA $1.87
- CRVO $2.43
- Average True Range (ATR)
- IPHA 0.12
- CRVO 0.17
- MACD
- IPHA -0.04
- CRVO 0.31
- Stochastic Oscillator
- IPHA 28.66
- CRVO 26.92
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.